- Investing Ideas
- Australian Biotech Stocks
Australian Biotech Stocks
Results
38
Even though biotechnology stocks can be very risky, they can also offer some of the biggest rewards with huge profits on offer when you find the right one. The companies below all have reasonable balance sheets and value, giving the best chance of finding a gem.
38 companies
CSL
Market Cap: AU$66.8b
Engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally.
CSL
AU$139.19
7D
0.2%
1Y
-40.3%
Mesoblast
Market Cap: AU$2.7b
Engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland.
MSB
AU$2.12
7D
-0.5%
1Y
34.6%
Neuren Pharmaceuticals
Market Cap: AU$1.6b
A biopharmaceutical company, develops drugs for the treatment of neurological disorders.
NEU
AU$12.52
7D
4.1%
1Y
36.2%
Clinuvel Pharmaceuticals
Market Cap: AU$456.3m
A biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.
CUV
AU$9.09
7D
0.8%
1Y
-14.2%
Orthocell
Market Cap: AU$222.5m
A regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally.
OCC
AU$0.82
7D
1.9%
1Y
-42.3%
Starpharma Holdings
Market Cap: AU$216.9m
A biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally.
SPL
AU$0.52
7D
3.0%
1Y
425.5%
Dimerix
Market Cap: AU$204.1m
A biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia.
DXB
AU$0.34
7D
6.3%
1Y
-13.9%
Aroa Biosurgery
Market Cap: AU$183.1m
Develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally.
ARX
AU$0.53
7D
-8.6%
1Y
35.9%
Mayne Pharma Group
Market Cap: AU$182.0m
A specialty pharmaceutical company, focuses on the commercialization of women’s health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally.
MYX
AU$2.24
7D
-3.9%
1Y
-67.9%
Bioxyne
Market Cap: AU$149.8m
Manufactures and distributes therapeutic goods, and health and wellness products in Australia, the United States, the United Kingdom, Czechia, Switzerland, France, Germany, and Japan.
BXN
AU$0.066
7D
3.1%
1Y
175.0%
Vita Life Sciences
Market Cap: AU$140.9m
A healthcare company, engages in formulating, packaging, distributing, and selling vitamins and supplements in Australia, Singapore, Malaysia, Thailand, Vietnam, Indonesia, and China.
VLS
AU$2.59
7D
3.2%
1Y
43.1%
Island Pharmaceuticals
Market Cap: AU$109.4m
A drug repurposing company, focuses on the development of antiviral therapeutics for antiviral therapeutics in Australia and the United States of America.
ILA
AU$0.37
7D
-1.3%
1Y
117.6%
Paradigm Biopharmaceuticals
Market Cap: AU$102.3m
Engages in the research and development of therapeutic products for human use in Australia.
PAR
AU$0.23
7D
-11.5%
1Y
-20.7%
Alterity Therapeutics
Market Cap: AU$97.9m
Engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson’s disease.
ATH
AU$0.009
7D
0%
1Y
12.5%
Botanix Pharmaceuticals
Market Cap: AU$79.9m
Operates as a commercial dermatology company in Australia and the United States.
BOT
AU$0.036
7D
-10.0%
1Y
-89.9%
Radiopharm Theranostics
Market Cap: AU$78.0m
A clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs.
RAD
AU$0.022
7D
4.8%
1Y
-4.3%
LTR Pharma
Market Cap: AU$75.4m
A clinical-stage pharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia.
LTP
AU$0.41
7D
2.5%
1Y
9.2%
Trajan Group Holdings
Market Cap: AU$60.3m
Develops, manufactures, and sells analytical and life science products and devices in Malaysia, Japan, Australia, New Zealand, the United States, Europe, the Middle East, Africa, and India.
TRJ
AU$0.40
7D
-3.7%
1Y
-54.1%
Immutep
Market Cap: AU$58.9m
A biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia.
IMM
AU$0.04
7D
-9.1%
1Y
-83.3%
Prescient Therapeutics
Market Cap: AU$58.9m
A clinical stage oncology company, develops drugs for the treatment of haematological and solid cancers in Australia.
PTX
AU$0.056
7D
7.7%
1Y
33.3%
Neurizon Therapeutics
Market Cap: AU$58.8m
A clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases.
NUZ
AU$0.083
7D
2.5%
1Y
-21.0%
Imugene
Market Cap: AU$50.0m
A clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia.
IMU
AU$0.14
7D
-3.4%
1Y
-82.8%
Medical Developments International
Market Cap: AU$46.8m
Manufactures and distributes emergency medical solutions in Australia, Asia, Europe, the United States, and internationally.
MVP
AU$0.41
7D
1.2%
1Y
-17.0%
Avecho Biotechnology
Market Cap: AU$34.9m
A biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and India.
AVE
AU$0.0095
7D
5.6%
1Y
90.0%
BCAL Diagnostics
Market Cap: AU$33.9m
A screening and diagnostic company, engages in developing a novel blood screening test to improve the diagnosis and monitoring of breast cancer.
BDX
AU$0.092
7D
-7.1%
1Y
3.4%
NeuroScientific Biopharmaceuticals
Market Cap: AU$33.3m
Engages in the research and development of biomedical products targeting neurodegenerative conditions.
NSB
AU$0.10
7D
0%
1Y
185.7%
Little Green Pharma
Market Cap: AU$29.7m
Engages in the cultivation, production, and distribution of medicinal cannabis products in Australia and internationally.
LGP
AU$0.097
7D
0%
1Y
-19.2%
Vitura Health
Market Cap: AU$27.2m
Engages in the sale and distribution of medicinal cannabis products in Australia.
VIT
AU$0.041
7D
7.9%
1Y
-43.8%
Peak Processing
Market Cap: AU$19.7m
Manufactures, distributes, and sells recreational cannabis products in Canada and the United States.
PKP
AU$0.017
7D
0%
1Y
-19.0%
IDT Australia
Market Cap: AU$19.7m
Engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API) and finished dose forms (FDF) products in Australia, Asia, Europe, and the United States.
IDT
AU$0.046
7D
7.0%
1Y
-54.0%
Genetic Signatures
Market Cap: AU$18.2m
Operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas.
GSS
AU$0.08
7D
0%
1Y
-78.7%
Tissue Repair
Market Cap: AU$9.7m
A clinical stage biopharmaceutical company, develops advanced wound healing products for chronic wounds and the aftercare of cosmetic procedures in Australia.
TRP
AU$0.16
7D
0%
1Y
-31.9%
Immuron
Market Cap: AU$8.8m
A biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada.
IMC
AU$0.027
7D
-3.6%
1Y
-59.7%
ECS Botanics Holdings
Market Cap: AU$8.0m
Engages in the cultivation, manufacture, and sale of medicinal cannabis products in Australia and internationally.
ECS
AU$0.005
7D
0%
1Y
-54.5%
Invion
Market Cap: AU$6.5m
A clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia.
IVX
AU$0.067
7D
-4.3%
1Y
-36.2%
Percheron Therapeutics
Market Cap: AU$5.4m
Engages in the research and development of novel antisense pharmaceuticals for cancer and rare diseases in Australia.
PER
AU$0.005
7D
0%
1Y
-50.0%